Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,363 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,720 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,404)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06594744 | Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC(P-HCC-CVL) | recruiting | Phase 4 | 120 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Feb 13, 2025 | clinicaltrials |
| NCT02405858 | A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy | completed | Phase 4 | 51 | Janssen Pharmaceutical K.K.INDUSTRY |
| 1 |
| Feb 3, 2025 |
| clinicaltrials |
| NCT05848947 | SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA(MAApping) | completed | Phase 4 | 5 | Sirtex MedicalINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT03285763 | A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)(TAIL) | completed | Phase 4 | 619 | Hoffmann-La RocheINDUSTRY | 24 | Jan 23, 2025 | clinicaltrials |
| NCT06785584 | Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study | not yet recruiting | Phase 4 | 30 | Fujian Medical University Union HospitalOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06784986 | Impact of Using the Airseal System With Ultra-low Pneumoperitoneum in Patients Undergoing Robot-assisted Radical Prostatectomy: A Prospective, Comparative, Randomized Clinical Study.(ARCO2) | recruiting | Phase 4 | 200 | Brazilian Institute of Robotic SurgeryOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04134208 | An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer | terminated | Phase 4 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT05894694 | Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer | recruiting | Phase 4 | 320 | Guang'anmen Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04541706 | Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India | completed | Phase 4 | 100 | PfizerINDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03656549 | Dose Individualization of Pemetrexed - IMPROVE-I(IMPROVE-I) | completed | Phase 4 | 6 | Radboud University Medical CenterOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT01977651 | A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide(UPWARD) | completed | Phase 4 | 424 | Astellas Pharma Global Development, Inc.INDUSTRY | 20 | Dec 6, 2024 | clinicaltrials |
| NCT02116582 | A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer | completed | Phase 4 | 215 | Astellas Pharma Europe B.V.INDUSTRY | 5 | Dec 6, 2024 | clinicaltrials |
| NCT03134456 | Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX | completed | Phase 4 | 50 | Samsung Medical CenterOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06390111 | A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.(ABLE-42) | withdrawn | Phase 4 | 0 | Ferring PharmaceuticalsINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT03024684 | Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment(SHOT) | active not recruiting | Phase 4 | 240 | Chiayi Christian HospitalOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04416633 | Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC | completed | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT03821376 | Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS) | terminated | Phase 4 | 12 | Indiana UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05250648 | Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)(GECOP-MMC) | recruiting | Phase 4 | 216 | Hospital Universitario de FuenlabradaOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06464380 | Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma | not yet recruiting | Phase 4 | 40 | Ain Shams UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06590844 | "cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma | unknown | Phase 4 | 37 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06483009 | Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC | not yet recruiting | Phase 4 | 20 | Shanghai Chest HospitalOTHER | 0 | Aug 30, 2024 | clinicaltrials |
| NCT06215976 | The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer | unknown | Phase 4 | 78 | Cairo UniversityOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT05748093 | Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat(OSIBOOST 2) | unknown | Phase 4 | 60 | Maastricht University Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05583188 | Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC(VIGOR) | terminated | Phase 4 | 5 | Galvanize Therapeutics, Inc.INDUSTRY | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06496815 | Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy | not yet recruiting | Phase 4 | 32 | Tongji HospitalOTHER | 0 | Jul 11, 2024 | clinicaltrials |
| NCT04790305 | Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer | recruiting | Phase 4 | 1,072 | Fudan UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06467786 | Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer | recruiting | Phase 4 | 24 | Tang-Du HospitalOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT04641819 | Yangzheng Compound Mixture in the Treatment of Sleep Disorder in Cancer Patients | unknown | Phase 4 | 1,127 | ShuGuang HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06417606 | Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 20 | Zhiyong HuangOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT04562428 | The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial | completed | Phase 4 | 10 | China Medical University HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05525338 | Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels(ADAPT ALEC) | recruiting | Phase 4 | 196 | University Medical Center GroningenOTHER | 2 | May 13, 2024 | clinicaltrials |
| NCT03712969 | Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC | completed | Phase 4 | 527 | West China HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06398028 | The Preoperative Administration of ICG Improves Tumor Detection in Patients Undergoing Minimally Invasive Hepatic Resection Guided by Conventional Intraoperative Ultrasound. | recruiting | Phase 4 | 173 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06388135 | Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 4 | 80 | Yang Jianjun, PhDOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT06357598 | Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer(PILOT) | unknown | Phase 4 | 30 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT04511533 | Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | completed | Phase 4 | 101 | PfizerINDUSTRY | 1 | Apr 5, 2024 | clinicaltrials |
| NCT06311916 | Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. | not yet recruiting | Phase 4 | 312 | Chen XiaopingOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT05124002 | Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 66 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06041425 | The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE | completed | Phase 4 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06217185 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | recruiting | Phase 4 | 100 | Hebei Medical University Fourth HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05803096 | Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain | completed | Phase 4 | 143 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT04180176 | Prospective Clinicogenomic Program(PCG) | completed | Phase 4 | 945 | Genentech, Inc.INDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04401059 | Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study(SELECT-2) | unknown | Phase 4 | 744 | Tian XieOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04297254 | A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC | completed | Phase 4 | 50 | Eisai Pharmaceuticals India Pvt. LtdINDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT04569799 | Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE(TACE) | completed | Phase 4 | 26 | Milton S. Hershey Medical CenterOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06115174 | Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer(CRC - PTX) | unknown | Phase 4 | 44 | Tanta UniversityOTHER | 0 | Nov 2, 2023 | clinicaltrials |
| NCT06003673 | A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC | unknown | Phase 4 | 20 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05071703 | Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study | completed | Phase 4 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Feb 13, 2025source: clinicaltrials